http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#Head
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#assertion
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#provenance
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#pubinfo
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#assertion
http://purl.obolibrary.org/obo/DOID_9538
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_9538
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB08889
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#association
http://www.w3.org/2000/01/rdf-schema#label
kyprolis is a proteasome inhibitor that is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy 1 14 as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy 1 14 kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB08889
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#provenance
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#pubinfo
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#sig
http://purl.org/nanopub/x/hasSignature
NxxsLEtdJs5vMx86r8GDwy5PKJANRgBWxXugAxiVedIKqOYzo1gpCrPeEbmy/zSfwkkJHrl2z5y+FKA9+iLScF4pOthcgmcEFrlHArH1Bw4cIWNkCvfgrLrVzCBOIJsriU28HSV/+2+h+Jbm/D+sNTL3aWmz2oVvDdoVM61t+R0=
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4
http://purl.org/dc/terms/created
2021-06-12T14:54:49.698+02:00
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs